Last updated: July 25, 2026
Array BioPharma, Inc. v. Alembic Pharmaceuticals Limited (D. Del., case no. 1:22-cv-01277) is a branded-on-generic patent dispute tied to Alembic’s regulatory filing seeking entry against Array’s marketed oncology product portfolio. The litigation’s practical posture is clear from the parties and venue: Array is asserting infringement of Orange Book-listed patent rights, while Alembic is contesting at least one asserted patent via invalidity and non-infringement defenses and, in the typical Hatch-Waxman structure, likely a Paragraph IV challenge framework.
But a complete, accurate litigation summary (claims asserted, asserted patents and their expiration dates, Mylan/Alembic filing details, claim construction outcomes, motion rulings, settlement terms, and the current procedural status) cannot be produced from the information provided in the prompt alone.
What patents are asserted in Array BioPharma v. Alembic (1:22-cv-01277)?
A litigation-ready map requires the specific asserted patent numbers and the asserted counts (and product/formulation/method-of-use linkage). That data is not present in the prompt.
Which Orange Book patents are at issue?
Orange Book listing identification typically drives:
- which patents Array selected for infringement theories
- whether any asserted patents are formulation, method-of-use, or manufacturing-related
- the relevance of patent-by-patent validity defenses (anticipation/obviousness, written description, enablement, indefiniteness)
What is the active ingredient and product scope in the case?
The active product identity determines:
- whether the dispute is method-of-use focused (common in oncology) versus formulation/device focused
- whether FDA labeling and prescribing information are central to infringement or claim construction
What Paragraph IV challenges does Alembic raise in 1:22-cv-01277?
A substantive Paragraph IV analysis requires:
- the ANDA/BLA (or 505(b)(2)) identification
- the specific listed patents and Alembic’s “certification” positions (e.g., “not infringed,” “invalid,” “no invalidity,” “will not infringe,” or carve-outs)
- any notice-of-certification date and amendments
Those case-specific filing artifacts are not included in the prompt.
What did the court rule on in Array BioPharma v. Alembic?
A litigation summary that can support business decisions needs the docket outcomes in sequence:
- Rule 12/35 motions, transfer/venue issues, or preliminary injunction motions (if any)
- claim construction rulings (Markman) and the court’s claim terms
- dispositive rulings on infringement/invalidity
- scheduling and discovery milestones
- any summary judgment orders or trial setting outcomes
No docket rulings are provided in the prompt, so no accurate “what the court ruled” summary can be produced.
Has the case been settled, and what is the settlement impact on generic entry?
Settlement terms typically dictate:
- design-around scope (label carve-outs, formulation changes)
- launch dates and royalty/licensing structures
- covenant-not-to-sue coverage or patent release scope
- terms affecting FDA tentative approval timing or “worksharing” implementation
No settlement date or terms are included in the prompt.
What is the current procedural posture of the case (as of today)?
A posture readout must reflect:
- last docket entry date
- whether the matter is stayed pending appeal, in trial, resolved by dismissal, or pending post-judgment motions
- any PTAB-related stays (inter partes review) if asserted
The prompt does not supply docket status.
What is Array’s patent estate strength in this litigation?
A patent strength analysis requires:
- asserted claims and independent/dependent claim structure
- prosecution history signals (narrowing amendments, disclaimer, or conceded limitations)
- claim scope relative to the accused product attributes
- available prior art landscape and obviousness combinations
- whether any asserted claims are likely to be upheld based on recent claim construction or final validity determinations in related cases
Without asserted patent numbers, claims, and court outcomes, no strength assessment can be produced.
Which companies are challenging Array’s patents alongside Alembic?
A competitive landscape analysis depends on the broader Hatch-Waxman cluster:
- whether other ANDA filers are co-litigants or parallel defendants
- whether multiple Paragraph IV filers target the same listed patents
- whether multiple cases share the same asserted patents or differ by formulation/method-of-use coverage
No parallel-case list is provided.
How does this case compare with other Array BioPharma patent litigations?
A comparison needs:
- which patents overlap across Array’s other disputes
- differences in accused product formulation or labeling
- different outcomes or claim construction differences that affect the common patent core
No other cases or their outcomes are supplied.
What generic entry risks exist for Alembic if Array prevails or if Alembic wins?
This requires FDA pathway timing and injunction risk:
- launch timing relative to any statutory exclusivity, patent expiry, or court-ordered stay
- whether a win triggers immediate launch or requires post-judgment appellate timing
- whether any partial invalidity leaves residual asserted patents still blocking entry
No FDA regulatory milestones, ANDA status, or court directives are provided.
What Orange Book status drives the case (expiration dates and exclusivity)?
A correct Orange Book summary depends on:
- patent numbers, listed expiration (including pediatric exclusivity if applicable)
- whether any exclusivity is tied to 5-year, 3-year, or other periods beyond patents
- whether each asserted patent is still in force and listed as of the relevant dates
No Orange Book data is included in the prompt.
Key Takeaways
- The case caption and docket number identify the forum and parties, but the prompt does not provide the litigation record needed for a complete, accurate infringement/validity summary.
- A business-useful summary requires the asserted patent numbers, claim themes, docket rulings, and current posture. Those elements are not present in the prompt, so no defensible conclusions can be produced.
FAQs
- What is the typical Hatch-Waxman claim structure when a branded sponsor sues an ANDA filer like Alembic?
- How do claim construction rulings usually affect the infringement and validity workflow in D. Del. Hatch-Waxman cases?
- What forms of relief (injunction, declaratory judgment of invalidity/non-infringement) typically determine the launch timeline after a win?
- How do PTAB IPR outcomes commonly interact with district court patent infringement timelines?
- What Orange Book listing attributes (formulation vs method-of-use vs manufacturing) most strongly influence infringement theories in oncology?
References
- No sources are provided in the prompt.
